lundi 26 décembre 2011

Focus: antibody-based therapeutics to watch in 2011

According to Janice Reichert (*), as of early November 2011, a total of 25 antibody-based therapeutics in Phase 3 are to watch in 2012:  AMG 386, bapineuzumab, elotuzumab, epratuzumab, factor VIII-Fc, factor IX-Fc, farletuzumab, girentuximab, inotuzumab ozogamicin, itolizumab, mepolizumab, naptumomab estafenatox, necitumumab, obinutuzumab, ocrelizumab, pertuzumab, ramucirumab, reslizumab, sarilumab, secukinumab, solanezumab, tabalumab, trastuzumab emtansine, vedolizumab, zanolimumab

(*) Antibody-based therapeutics to watch in 2011. Janice M. Reichert ( Landes Bioscience; Austin, TX USA
Free article available at:

Antibody-based therapeutics in Phase 3 studies as treatments for cancer indications

International non-proprietary name

Target; description
Indication of Phase 3 study

Naptumomab estafenatox
Fab conjugated to
staphylococcal enterotoxin A
5T4; Fab conjugated to staph.
enterotoxin A
Advanced renal cell carcinoma
AMG 386
Peptibody composed of a peptide fused with an Fc
Angiopoietin-1 and -2;
target-binding peptide fused
to Fc of human IgG1
Epithelial ovarian, primary peritoneal or
fallopian tube cancers
Canonical IgG1
Carbonic anhydrase ix; IgG1
Non-metastatic renal cell carcinoma
Canonical IgG1
CD2; IgG1
Multiple myeloma
Canonical IgG1
CD4; IgG1
Mycosis fungoides or Sezary syndrome
CD20; glyco-engineered IgG1

Chronic lymphocytic leukemia; non-Hodgkin
lymphoma; advanced diffuse large
B-cell lymphoma
Inotuzumab ozogamicin
Antibody-drug conjugate (ADC)
CD22; IgG1 conjugated to

Relapsed/refractory aggressive
non-Hodgkin lymphoma
Canonical IgG1
Non-small cell lung cancer
Canonical IgG1
Folate receptor α; IgG1
Ovarian cancer; adenocarcinoma of the lung
Trastuzumab emtansine
Antibody-drug conjugate (ADC)
HER2; IgG1 conjugated to DM1
Locally advanced or metastatic breast cancer
Canonical IgG1
HER2; IgG1
Metastatic breast cancer
Canonical IgG1
Metastatic gastric or gastroesophageal junction adenocarcinoma; breast cancer;
non-small cell lung cancer;
hepatocellular carcinoma; colorectal cancer

Note: Information current as of October 31, 2011.

Abbreviations: CD, cluster of differentiation; EGFR, epidermal growth factor receptor; Fab, antigen-binding fragment; HER2, human epidermal growth factor receptor; VEGFR2, vascular endothelial cell growth factor receptor 2. International non-proprietary naming convention: -umab, human; -zumab, humanized; -ximab, chimeric; -momab, murine.

Aucun commentaire:

Enregistrer un commentaire